Abivax SA (NASDAQ:ABVX) is preparing to raise capital following the release of key clinical trial data in June, signaling a preference for independent growth despite ongoing acquisition speculation, CEO Marc de Garidel told CNBC.

• Abivax stock is taking a hit today. Why is ABVX stock falling?

The French biotech firm has been at the center of takeover rumors for months, with analysts identifying it as a potential acquisition target for large pharmaceutical companies.

Recently, AstraZeneca Plc (NYSE:AZN) emerged as the leading contender to acquire the French biotech. The company later rebuffed the media reports.

Eli Lilly and Co (NYSE:LLY) previously expressed interest.

But management's latest comments suggest the company is not under pressure to sell and is instead focused on strengthening its financial position ahead of a potential commercialization phase.

Upcoming Trial Seen As Major Catalyst

Investor attention is firmly ...